Thanh Le Quang, Chen Yipu, Hartweg Mickaël, Thi Nguyen Tu Anh
Tu Du Hospital, Hồ Chí Minh, Viet Nam.
Nestlé Product Technology Center - Nutrition, Société des Produits Nestlé SA, Vevey, Switzerland.
Pediatr Neonatol. 2022 May;63(3):227-238. doi: 10.1016/j.pedneo.2021.09.007. Epub 2021 Dec 4.
Preterm formulas containing greater protein:energy ratio are beneficial for non-breastfed infants, since protein is critical for promoting catch-up growth and synthesis of lean body mass. Additionally, formulas containing enriched sn-2 palmitate (sn-2) and reduced medium chain triglycerides (MCTs) may support better feeding tolerance and nutrient utilization.
The objective of this randomized, controlled, double-blinded clinical trial is to evaluate growth, feeding tolerance and nutritional biomarkers of preterm infants with birth weight ≤2000g and gestational age ≤33wks from one neonatal unit in Vietnam receiving experimental formula (EF, n = 80) containing higher protein level of 3.4 g/100 kcal and improved fat blend with enriched sn-2 and modified level of MCTs or isocaloric control formula (CF, n = 80) containing protein level of 2.9 g/100 kcal and standard fat blend. The differences in weight gain (g/d; primary endpoint) from day 1 (D1) of full enteral feeding (FEF) until D21 between groups was evaluated for non-inferiority (margin = -2.5 g/d) and superiority (margin = 0 g/d).
Mean weight gain was 3.09 g/d greater in EF than CF; the lower limit of 95% CI (0.31 g/d) exceeded both non-inferiority and superiority margins. There was no significant difference in length-for-age and head circumference-for-age z-score. By D79, the mean change in weight-for-age z-scores from D1 in EF group (+0.76 SDs) surpassed the criteria for catch-up growth (+0.67 SDs). Infants in the EF group (vs. CF) tended to have softer stools (EF = 3.2 ± 0.59 vs. CF = 3.4 ± 0.58; P = 0.07) based on 5-point scale (1 = watery, 5 = hard). Difference in blood urea nitrogen and biomarkers for bone mineral status (i.e., plasma phosphorus, alkaline phosphatase and urinary calcium/phosphorus ratio) between EF and CF on FEF Day 21 reached statistical significance (P < 0.05) but all mean values stayed within normal clinical ranges for both groups.
Preterm formula with greater protein:energy ratio and new fat blend is safe, nutritionally suitable, well-tolerated, and improves catch-up weight gain of preterm infants. Clinical trial registry identifier is NCT03055052 (ClinicalTrials.gov).
蛋白质能量比更高的早产儿配方奶粉对非母乳喂养的婴儿有益,因为蛋白质对于促进追赶生长和瘦体重合成至关重要。此外,含有丰富sn-2棕榈酸酯(sn-2)和减少中链甘油三酯(MCTs)的配方奶粉可能有助于更好的喂养耐受性和营养利用。
这项随机、对照、双盲临床试验的目的是评估来自越南一个新生儿病房的出生体重≤2000g且胎龄≤33周的早产儿的生长、喂养耐受性和营养生物标志物。这些早产儿接受实验配方奶粉(EF,n = 80),其蛋白质水平较高,为3.4 g/100 kcal,并改进了脂肪配方,含有丰富的sn-2且调整了MCTs水平;或接受等热量对照配方奶粉(CF,n = 80),其蛋白质水平为2.9 g/100 kcal且脂肪配方为标准配方。评估两组从完全肠内喂养(FEF)第1天(D1)到第21天体重增加(g/d;主要终点)的差异,以判断非劣效性(界值 = -2.5 g/d)和优越性(界值 = 0 g/d)。
EF组的平均体重增加比CF组多3.09 g/d;95%置信区间的下限(0.31 g/d)超过了非劣效性和优越性界值。年龄别身长和年龄别头围z评分无显著差异。到第79天,EF组从D1开始的年龄别体重z评分的平均变化(+0.76标准差)超过了追赶生长的标准(+0.67标准差)。基于5分制(1 = 水样便,5 = 硬便),EF组婴儿(与CF组相比)的粪便往往更软(EF = 3.2 ± 0.59 vs. CF = 3.4 ± 0.58;P = 0.07)。在FEF第21天,EF组和CF组之间的血尿素氮以及骨矿物质状态生物标志物(即血浆磷、碱性磷酸酶和尿钙/磷比值)的差异达到统计学意义(P < 0.05),但两组的所有平均值均保持在正常临床范围内。
蛋白质能量比更高且脂肪配方新颖的早产儿配方奶粉安全、营养适宜、耐受性良好,并能改善早产儿的追赶性体重增加。临床试验注册标识符为NCT03055052(ClinicalTrials.gov)。